Eli Lilly Beats Challenge To Cancer Treatment Patent
The U.S. Patent Trial and Appeal Board found Thursday that a patent protecting the vitamin regimen for one of drugmaker Eli Lilly & Co.'s best-selling cancer treatments, Alimta, is valid, rejecting...To view the full article, register now.
Already a subscriber? Click here to view full article